Zenas files new $200M stock offering as obexelimab BLA review continuesNov 6FinancingobexelimabZenas BioPharma (USA), LLCUpdated
Emergent BioSolutions cuts 2026 revenue and EBITDA guidance as Q3 sales fall 52%Nov 2Quarterly updateAmgenAprea Therapeutics
Zenas BioPharma reports Q2 2026 results, obexelimab BLA now accepted by FDAAug 13Quarterly updateobexelimabZenas BioPharma (USA), LLC
Xencor reports Q2 2026 results, sets ESMO date for XmAb819 kidney cancer dataAug 5Quarterly updateXencor, Inc.XMAB819